Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AbbVie Backs Studies On HIV Drug Kaletra For Coronavirus Cure

Published 03/10/2020, 10:17 PM
Updated 07/09/2023, 06:31 AM

AbbVie, Inc. (NYSE:ABBV) said it is working with global health authorities to determine the efficacy of its HIV medicine, Kaletra/Aluvia against COVID-19. AbbVie is coordinating with European health authorities, FDA, Centers for Disease Control and Prevention and other U.S. health agencies to support clinical studies on Kaletra/Aluvia for COVID-19 treatment. Kaletra/Aluvia is a combination of lopinavir and ritonavir.

AbbVie donated Aluvia to the government of China, after a request was made in January, for experimental use in COVID-19 treatment. AbbVie claims that Aluvia has reportedly been effective in treating COVID-19. However, the company ensured no disruption in the supply of Kaletra/Aluvia for HIV treatment due to the experimental use of this therapy against COVID-19.

AbbVie’s shares have risen 12.1% in the past year, outperforming the industry’s increase of 0.7%.

AbbVie is among the several biotech/drug companies working on making treatments/vaccines to treat COVID-19. With the situation in China getting worse and the risk of global coronavirus outbreak rising, faster development of medicines/vaccines is the need of the hour.

Coalition for Epidemic Preparedness Innovations (“CEPI”), a public-private non profit organization, has provided funding to biotechs like Moderna and Inovio Pharmaceuticals for developing a COVID-19 vaccine.

Apart from CEPI funded biotechs, several others like J&J (NYSE:JNJ) , Sanofi (PA:SASY), GlaxoSmithKline (NYSE:GSK) and Regeneron (NASDAQ:REGN) have expressed interest in developing a vaccine for COVID-19. The companies investing heavily in COVID-19 vaccine development are testing if their existing/pipeline vaccines for flu or infectious diseases like SARS (also caused by a coronavirus) could prove effective in halting COVID-19’s spread.

Meanwhile, the World Health Organization recommended Gilead’s investigational antiviral candidate, remdesivir as partial remedy for coronavirus though it has yet not been proven that the candidate can treat the disease. The leading biotech, last month, initiated two phase III studies, which will evaluate two dosing regimens of remdesivir in adults diagnosed with 2019-nCoV.

Other smaller biotechs like Vaxart and Novavax are making an effort to leverage their existing vaccine technology/platform to develop COVID-19 vaccine candidates.

Last week, President Donald Trump asked pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development. However, none of these vaccines/treatments are expected to be available before a year’s time.

AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>



Johnson & Johnson (JNJ): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.